Antifungal resistance to fluconazole and echinocandins is not emerging in yeast isolates causing fungemia in a Spanish tertiary care center

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 8, 2014, Pages 4565-4572

  Marcos Zambrano, Laura Judith ^a,b   Escribano, Pilar ^a,b,c   Sánchez, Carlos ^a,b   Muñoz, Patricia ^a,b,c,d   Bouza, Emilio ^a,b,c,d   Guinea, Jesús ^a,b,c,d  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d SCHOOL OF MEDICINE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ECHINOCANDIN; FUNGAL DNA; PYRROLE DERIVATIVE; SPACER DNA;

ANTIFUNGAL RESISTANCE; CANDIDA; CANDIDIASIS; DRUG EFFECTS; FUNGEMIA; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; SPAIN; TERTIARY HEALTH CARE;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; AZOLES; CANDIDA; CANDIDIASIS; DNA, FUNGAL; DNA, INTERGENIC; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FUNGEMIA; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOLOGICAL TYPING TECHNIQUES; SPAIN; TERTIARY HEALTHCARE;

EID: 84905378479     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02670-14     Document Type: Article

References (34)

1. Almirante B, Rodríguez D, Park BJ, Cuenca-Estrella M, Planes AM, Almela M, Mensa J, Sánchez F, Ayats J, Giménez M, Saballs P, Fridkin SK, Morgan J, Rodríguez-Tudela JL, Warnock DW, Pahissa A. 2005. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J. Clin. Microbiol. 43:1829-1835. http://dx.doi.org/10.1128/JCM. 43.4.1829-1835.2005.
2. Puig-Asensio M, Padilla B, Garnacho-Montero J, Zaragoza O, Aguado JM, Zaragoza R, Montejo M, Muñoz P, Ruiz-Camps I, Cuenca-Estrella M, Almirante B. 2014. Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population-based surveillance in Spain. Clin. Microbiol. Infect. 20:O245-O254. http://dx.doi.org/10.1111/1469-0691.12380.
3. Pemán J, Cantón E, Minana JJ, Flórez JA, Echeverría J, Ortega DN, Alarcón JM, Fontanals D, Sard BG, Moreno BB, Torroba L, Ayats J, Pérez MA, Fernández MA, Reus FS, Natal IF, García-Rodríguez J, Ezpeleta G, Martín-Mazuelos E, Iglesias I, Rezusta A, de Ocáriz IR, Nieto AG. 2011. Changes in the epidemiology of fungaemia and fluconazole susceptibility of blood isolates during the last 10 years in Spain: results from the FUNGEMYCA study. Rev. Iberoam Micol. 28:91-99. http://dx.doi.org/10.1016/j.riam.2011.02.005.
4. Pfaller M, Boyken L, Hollis R, Kroeger J, Messer S, Tendolkar S, Diekema D. 2011. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin. J. Clin. Microbiol. 49:624-629. http://dx.doi.org/10.1128/JCM.02120-10.
5. Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D. 2010. Wild-type MIC distributions, epidemiological cutoff values and speciesspecific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist. Updat. 13:180-195. http://dx.doi.org/10.1016/j.drup.2010.09.002.
6. Guinea J. 2014. Global trends in the distribution of Candida species causing candidemia. Clin. Microbiol. Infect. 20(Suppl 6):5-10. http://dx.doi.org/10.1111/1469-0691.12539.
7. Guinea J, Zaragoza O, Escribano P, Martín-Mazuelos E, Pemán J, Sánchez-Reus F, Cuenca-Estrella M. 2014. Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain from 2010 to 2011. Antimicrob. Agents Chemother. 58:1529-1537. http://dx.doi.org/10.1128/AAC.02155-13.
8. Arendrup MC, Bruun B, Christensen JJ, Fuursted K, Johansen HK, Kjaeldgaard P, Knudsen JD, Kristensen L, Moller J, Nielsen L, Rosenvinge FS, Roder B, Schonheyder HC, Thomsen MK, Truberg K. 2011. National surveillance of fungemia in Denmark (2004 to 2009). J. Clin. Microbiol. 49:325-334. http://dx.doi.org/10.1128/JCM.01811-10.
9. Brito LR, Guimaraes T, Nucci M, Rosas RC, Paula Almeida L, Da Matta DA, Colombo AL. 2006. Clinical and microbiological aspects of candidemia due to Candida parapsilosis in Brazilian tertiary care hospitals. Med. Mycol. 44:261-266. http://dx.doi.org/10.1080/13693780500421476.
10. Tavanti A, Davidson AD, Gow NA, Maiden MC, Odds FC. 2005. Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III J. Clin. Microbiol. 43:284-292. http://dx.doi.org/10.1128/ JCM.43.1.284-292.2005.
11. Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. 2011. Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). J. Clin. Microbiol. 49:396-399. http://dx.doi.org/10.1128/JCM.01398-10.
12. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Jr, Calandra TF, Edwards JE, Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update. Clin. Infect. Dis. 48:503-535. http://dx.doi.org/10. 1086/596757.
13. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S, Bille J, Castagnola E, Cuenca-Estrella M, Donnelly JP, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Florl C, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ. 2012. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin. Microbiol. Infect. 18(Suppl 7):S19-S37. http://dx.doi.org/10.1111/1469-0691.12039.
14. Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F. 2011. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2, 441 patients. Antimicrob. Agents Chemother. 55:532-538. http://dx.doi.org/10.1128/ AAC.01128-10.
15. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). 2008. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin. Microbiol. Infect. 14:398-405. http://dx.doi.org/10.1111/j.1469-0691.2007.01935.x.
16. Escribano P, Recio S, Peláez T, Sánchez-Carrillo C, Rodríguez-Créixems M, Muñoz P, Bouza E, Guinea J. 2012. Molecular identification of yeasts causing fungaemia: are cryptic species frequent? Abstr. 22nd Eur. Congr. Clin. Microbiol. Infect. Dis. (ECCMID), abstr. p 834.
17. Marcos-Zambrano LJ, Escribano P, Muñoz P, Bouza E, Guinea J. 2014. Low rate of cryptic species and antifungal resistance in Candida isolates causing candidaemia in Madrid Abstr. 24th Eur. Congr. Clin. Microbiol. Infect. Dis. (ECCMID), abstr. eP-234.
18. White T, Bruns T, Lee S, Taylor J. 1990. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics, p 322. In PCR protocols: guide to methods and applications. Academic Press, San Diego, CA.
19. Arendrup MC, Cuenca-Estrella M, Lass-Florl C, Hope W. 2012. EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts, EDef 7.2 (EUCAST-AFST). Clin. Microbiol. Infect. 18:E246-E247. http://dx.doi.org/10.1111/j.1469-0691.2012.03880.x.
20. Arendrup MC, Cuenca-Estrella M, Lass-Florl C, Hope WW. 2013. Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. Drug Resist. Updat. 16:81-95. http://dx.doi.org/10.1016/j.drup.2014.01.001.
21. Arendrup MC, Rodriguez-Tudela JL, Park S, Garcia-Effron G, Delmas G, Cuenca-Estrella M, Gomez-Lopez A, Perlin DS. 2011. Echinocandin susceptibility testing of Candida spp. Using EUCAST EDef 7.1 and CLSI M27-A3 standard procedures: analysis of the influence of bovine serum albumin supplementation, storage time, and drug lots. Antimicrob. Agents Chemother. 55:1580-1587. http://dx.doi.org/10.1128/AAC.01364-10.
22. Espinel-Ingroff A, Arendrup MC, Pfaller MA, Bonfietti LX, Bustamante B, Canton E, Chryssanthou E, Cuenca-Estrella M, Dannaoui E, Fothergill A, Fuller J, Gaustad P, Gonzalez GM, Guarro J, Lass-Florl C, Lockhart SR, Meis JF, Moore CB, Ostrosky-Zeichner L, Pelaez T, Pukinskas SR, St-Germain G, Szeszs MW, Turnidge J. 2013. Interlaboratory variability of caspofungin MICs for Candida spp. using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob. Agents Chemother. 57:5836-5842. http://dx.doi.org/10.1128/AAC.01519- 13.
23. European Committee on Antimicrobial Susceptibility Testing. 2010. Voriconazole: rationale for the clinical breakpoints, version 2.0. http://www.eucast.org.
24. European Committee on Antimicrobial Susceptibility Testing. 2010. Posaconazole: rationale for the clinical breakpoints, version 1.0. http://www.eucast.org.
25. European Committee on Antimicrobial Susceptibility Testing. 2013. Micafungin and Candida spp.: rationale for the clinical breakpoints, version 1.0. http://www.eucast.org.
26. Aller AI, Martin-Mazuelos E, Lozano F, Gomez-Mateos J, Steele-Moore L, Holloway WJ, Gutierrez MJ, Recio FJ, Espinel-Ingroff A. 2000. Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob. Agents Chemother. 44:1544-1548. http://dx.doi.org/10.1128/AAC.44.6.1544-1548. 2000.
27. Desnos-Ollivier M, Bretagne S, Raoux D, Hoinard D, Dromer F, Dannaoui E. 2008. Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob. Agents Chemother. 52:3092-3098. http://dx.doi.org/10.1128/AAC.00088- 08.
28. Garcia-Effron G, Park S, Perlin DS. 2009. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob. Agents Chemother. 53:112-122. http://dx.doi.org/10.1128/AAC.01162-08.
29. Pemán J, Cantón E, Quindós G, Eraso E, Alcoba J, Guinea J, Merino P, Ruiz-Pérez-de-Pipaón MT, Pérez-del- Molino L, Linares-Sicilia MJ, Marco F, García J, Roselló EM, Gómez de la Pedrosa G, Borrell N, Porras A, Yague G. 2012. Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey. J. Antimicrob. Chemother. 67:1181-1187. http://dx.doi.org/10.1093/jac/dks019.
30. Cornet M, Sendid B, Fradin C, Gaillardin C, Poulain D, Nguyen HV. 2011. Molecular identification of closely related Candida species using two ribosomal intergenic spacer fingerprinting methods. J. Mol. Diagn. 13:12-22. http://dx.doi.org/10.1016/j.jmoldx.2010.11.014.
31. Xu J, Millar BC, Moore JE, McClurg R, Walker MJ, Evans J, Hedderwick S, McMullan R. 2002. Comparison of API20C with molecular identification of Candida spp. isolated from bloodstream infections. J. Clin. Pathol. 55:774-777. http://dx.doi.org/10.1136/jcp.55.10.774.
32. Yong PV, Chong PP, Lau LY, Yeoh RS, Jamal F. 2008. Molecular identification of Candida orthopsilosis isolated from blood culture. Mycopathologi. 165:81-87. http://dx.doi.org/10.1007/s11046-007-9086-8.
33. Alexander BD, Johnson MD, Pfeiffer CD, Jimenez-Ortigosa C, Catania J, Booker R, Castanheira M, Messer SA, Perlin DS, Pfaller MA. 2013. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin. Infect. Dis. 56:1724-1732. http://dx.doi.org/10.1093/cid/cit136.
34. Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M. 2013. Echinocandin and triazole antifungal susceptibility profiles of opportunistic yeast and mould clinical isolates (2010-2011): Application of new CLSI clinical breakpoints and epidemiological cutoff values to characterize geographic and temporal trends of antifungal resistance. J. Clin. Microbiol. 51:2571-2581. http://dx.doi.org/10.1128/JCM.00308-13.